Blue Cross Blue Shield of North DakotaCommercial · Prior Auth · Pharmacy · ND · Oncology, PharmacyMedium impact
Pharmacy Policies Available Online
Act
by Oct 31, 2026
Effective date
Nov 1, 2026
Identified
Aug 29, 2026
Summary
Blue Cross Blue Shield of North Dakota (BCBSND) is implementing new commercial prior authorization medical drug policies effective November 1, 2026, for four specialty pharmaceutical products: Bendamustine-Avyxa, Lytenava (bevacizumab-vikg), Ponlimsi (denosumab-adet), and Tudriqev (vusolimogene oderparepvec-wtpg). Billing teams must prepare systems to require prior authorization for these drugs starting on the effective date.
Get alerts when payers change rules like this one
We check Blue Cross Blue Shield of North Dakota and other payers every day and email you when a change matches your specialty and state.
01Billing team must update the billing system to require prior authorization for Bendamustine-Avyxa, Lytenava (bevacizumab-vikg), Ponlimsi (denosumab-adet), and Tudriqev (vusolimogene oderparepvec-wtpg) for all BCBSND commercial plans.
02Configure system to route claims for these drugs to Gateway PA portal (www.gatewaypa.com/policydisplay/52) for approval before processing.
03Alert prescribing providers and clinical staff that prior authorization is now required for these four medications.
04Failure to obtain prior authorization will result in claim denials.
05Contact BCBSND Provider Services at 800-368-2312 for policy clarification.
Codes mentioned
J9045J9035J3396J3399
Original notice
Pharmacy Policies Available Online
bcbsnd.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.